OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC by Wermke, M., Kuboki, Y., Felip, E., Alese, O.B., Morgensztern, D., Sayehli, C., Arriola, E., Sanmamed, M.F., Oum’ Hamed, Z., Song, E., Studeny, M., Gambardella, V.

Get full text